• Biomolecules & Therapeutics
• /
• v.4 no.4
• /
• pp.310-313
• /
• 1996

Acute oral toxicity studies of KDRD-002 (Coriolus versicolor polysaccharide :DDB= 19.2:1) were carried out in Sprague-Dawley rats of both sexes. In this study, we daily examined number of deaths, clinical signs, body weights and pathological examinations for 7 days after single oral administration of KDRD-002 with different dose levels. KDRD-002 did not show any toxic effect in rats and oral LD$_{50}$ value was over 3.25 g/kg in rats.s.

• Biomolecules & Therapeutics
• /
• v.4 no.4
• /
• pp.314-322
• /
• 1996

The subacute toxicity was investigated in Sprague-Dawley rats orally treated with KDRD-010 at the doses of 0.056, 0.28, and 1.4 g/kg for one month. There were no clinical signs and pathological changes compared with control group. Body weights were not significantly changed between control and treatment groups. In hematological and biochemical serum parameters, all mean values appear to be within the normal range. In pathological examinations, hemorrhages of lung was observed in one male rat at low dose group and one female rat at high dose group of KDRD-010, but it was not considered to be caused by KDRD-010. These results suggest that KDRD-010 dose not induce any significant subacute oral toxicities in Sprague-Dawley rats.

• Journal of Korean Neurosurgical Society
• /
• v.38 no.1
• /
• pp.16-22
• /
• 2005

Objective : The authors characterize a syndrome of multiple neurogenic tumors in the spinal canal, which is unclassifiable by the current National Institute of Health[NIH] criteria for neurofibromatosis. Methods : We retrospectively examined cases in which two or more spinal neurogenic tumors were detected by magnetic resonance[MR] imaging and which had been pathologically confirmed. Eighteen patients were recruited between February 1986 and March 2002. According to NIH criteria, eight cases were neurofibromatosis type 1[NF1], four were type 2[NF2], and six were neither type 1 nor type 2 [Unclassifiable : UC]. The locations of lesions, clinical presentations, radiological findings, and pathological results with immunohistochemistry were reviewed. Results : In the case of NF2, three of four cases were intradural tumors. Pathological examinations revealed neurilemmomas in two of four NF2 and all of the UC cases. In the case of NF1, pathological examinations showed seven neurofibromas and one neurilemmoma. Concerning UC, the age at presentation was middle-aged to late [mean age 48.5, range 35 to 64], which contrasted with ordinary NF2, where patients tended to become symptomatic before 20years of age. The pathological examinations of UC cases revealed neurilemmoma similar to most of NF2 and the immunohistochemical study showed characteristic of NF1. Conclusion : Multiple neurogenic tumors in the spinal canal are an under-recognized disease entity. Further studies for genetic aberration in multiple spinal neurogenic tumors are needed.

• Toxicological Research
• /
• v.12 no.2
• /
• pp.323-330
• /
• 1996

Subacute toxicity study was performed in Sprague-Dawley rats after daily oral administration of KDRD-002 0.23, 0.7, 2.1 g/kg for one month. There were no clinical signs and pathological changes compared with control group but slight decrease in spontaneous motor activities and locomotions at high dose group of KDRD-002. Body weights were not significantly changed between control and KDRD-002 treated groups. In histopathological examinations, however, two animals (1 male, 1 female) showed abnormal increases in the weights of spleen tissues at middle dose group of KDRD-002. Also, there were some hemorrhages in lung tissues at low dose group of KDRD-002, but it was not considered to be caused by KDRD-002. These results suggest that KDRD-002 does not induce any significant subacute oral toxicity in Sprague-Dawley rats.

• Toxicological Research
• /
• v.12 no.2
• /
• pp.319-322
• /
• 1996

This study was carried out to investigate the acute toxicity of KDRD-010 in Sprague-Dawley rats. KDRD-010 was administratered orally at a dose level of 26, 78, 233, 700, and 2,100 mg/kg. In this study, we daily examined number of deaths, clinical signs, body weights, and pathological examinations for 14 days after administration of KDRD-010. The results indicate that KDRD-010 did not show any toxic effect in rats and oral $LD_50$ value was over 2,100 mg/kg in Sprague-Dawley rats.

• Toxicological Research
• /
• v.18 no.4
• /
• pp.397-400
• /
• 2002

This study was carried out to investigate the acute toxicity of G. bimaculatus in Sprague-Dawley rats. G. bimaculatus was administered orally at doses of 8, 40, 200, 1000 and 5000 mg/kg. in this study, number of deaths, clinical sign, body weights, and pathological examination were investigated for 14 days after administration of G. bimaculatus. The results indicate that G. bimaculatus did not show any toxic effect in rats and oral $LD_{50}$ value was over 5000 mg/kg in Sprague-Dawley rats.

• Toxicological Research
• /
• v.14 no.3
• /
• pp.411-414
• /
• 1998

The acute toxicity of DWP-311 was investigated in Sprague-Dawley rats. DWP-311 was subcutaneously administratered at dose levels of 595, 1,070, 1,930, 3,470, and 6,250mg/kg. In this study, we daily examined numbers of deaths, clinical signs, body weights, and pathological examinations for 7 days after administration of DWP-311. The results indicate that DWP-311 did not show any toxic effect in rats and the oral $LD_{50}$ value was over 6,250mg/kg in Sprague-Dawley rats.

• Toxicological Research
• /
• v.11 no.1
• /
• pp.147-155
• /
• 1995

HRccine was administered subcutaneously for 4 weeks to rabbits at dose levels of 300, 60 and 12 times the expected clinical dose to evaluate the subacute toxicity. There were no effects in clinical signs, body weight changes, food consumption, water consumption, urinalysis and blood biochemistry in any animals tested. In hematological examinations, decrease of lymphocyte counts and increase of platelet counts were observed in the medium- and high-dose treated groups. Absolute weights of thymus were tending to decrease, but no pathological changes were observed in microscopic examinations. The no-effect dose in subacute toxicity study of rabbits was considered to be 300 times the expected clinical dose.

• Toxicological Research
• /
• v.11 no.1
• /
• pp.137-145
• /
• 1995

HRccine was administered subcutaneously to rats for 4 weeks at dose levels of 300, 60 and 12 times the expected clinical dose to evaluate the subacute toxicity. There were no treatment-related effects in clinical signs, body weight changes, food consumption, water consumption, urinalysis and blood biochemistry in any dose groups. In hematological examinations, increase of leucocyte counts and decrease of hemoglobin concentration were observed in the high dose-treated group. However, no treatment-attributable pathological changes were observed in microscopic examinations. The no-effect dose in subacute toxicity study of rats was considered to be 300 times the expected clinical dose.

• Biomolecules & Therapeutics
• /
• v.6 no.3
• /
• pp.328-336
• /
• 1998

The subacute oral toxicity study of DWP-311 was carried out in Sprague-Dawley rats of both sexes. We daily examined clinical signs, body weights, hematological and biochemical parameters, and histopathological examinations for 30 days after administration of DWP-311 with different dose levels (0, 0.04, 0.2, and 1.0 g/kg). There were no clinical signs and pathological changes compared with control group except slight decreases in spontaneous motor activities and locomotions at high dose group of DWP-311. Body weights were not significantly changed in animals treated with DWP-311, In histopathological examinations, there were 2 cases of pneumonia in control group for one male and one female, but it was not directly related to DWP-311. These results indicate that subacute oral toxicities of DWP-311 were low and the no-observed a dverse effect level (NOAEL) was considered to be 1.0 g/kg in rats.